DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
- Conditions
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 145
- Registration Number
- NCT04526691
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇯🇵Showa Univeristy Hospital, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 666
- Registration Number
- NCT04519944
- Locations
- 🇩🇪
Zentralklinik Bad Berka, Bad Berka, Germany
🇩🇪Kerckhoff-Klinik GmbH, Bad Nauheim, Germany
🇩🇪SLK-Kliniken Heilbronn GmbH Klinikum am Plattenwald, Bad Friedrichshall, Germany
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 137
- Registration Number
- NCT04484142
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute at Florida Cancer Center, South, Port Charlotte, Florida, United States
🇺🇸UCLA, Santa Monica, California, United States
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT04479436
- Locations
- 🇬🇧
Sarah Cannon Research Institute UK, London, United Kingdom
🇯🇵Kindai University Hospital, Osaka, Osakasayama Shi, Japan
🇪🇸Hospital del Mar - Institut Hospital del Mar d'Investigacions Mediques IMIM, Barcelona, Spain
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
- Conditions
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 12
- Registration Number
- NCT04473664
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 34
- Registration Number
- NCT04276415
- Locations
- 🇺🇸
Washington University of St. Louis, Saint Louis, Missouri, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson, Houston, Texas, United States
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 28
- Registration Number
- NCT04276662
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Worldwide Clinical Trials, San Antonio, Texas, United States
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 16
- Registration Number
- NCT04223635
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 250
- Registration Number
- NCT04145622
- Locations
- 🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇯🇵Kindai University Hospital, Osaka-Sayama, Japan
🇺🇸Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 115
- Registration Number
- NCT04042701
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Univ. of Cali. San Francisco Medical Center, San Francisco, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States